MCID: HYP083
MIFTS: 58

Hypopituitarism

Categories: Rare diseases, Endocrine diseases, Genetic diseases

Aliases & Classifications for Hypopituitarism

MalaCards integrated aliases for Hypopituitarism:

Name: Hypopituitarism 12 76 53 37 29 55 44 15 73
Pituitary Insufficiency 12 53
Pituitary Hormone Deficiency 12
Pituitary Hypofunction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9406
ICD10 33 E23.0 E23
MeSH 44 D007018
NCIt 50 C62591
KEGG 37 H01700
UMLS 73 C0020635

Summaries for Hypopituitarism

NIH Rare Diseases : 53 Hypopituitarism occurs when the body has low levels of certain hormones made by the pituitary gland.  The pituitary gland normally makes several hormones (including growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, prolactin, follicle stimulating hormone and luteinizing hormone, vasopressin, and oxytocin).  These hormones are important for directing body growth and development, and for regulating blood pressure and metabolism.  Symptoms of this condition vary and depend on which hormones are affected.  Treatment depends on the cause of this condition; once the cause is corrected, medication (hormone replacement therapy) must be taken to provide the body with the normal amount of hormones.

MalaCards based summary : Hypopituitarism, also known as pituitary insufficiency, is related to pallister-hall syndrome and lymphocytic hypophysitis. An important gene associated with Hypopituitarism is PROP1 (PROP Paired-Like Homeobox 1), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and p70S6K Signaling. The drugs Hydrocortisone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland.

Wikipedia : 76 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypopituitarism

Diseases in the Hypopituitarism family:

Familial Hypopituitarism

Diseases related to Hypopituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 363)
# Related Disease Score Top Affiliating Genes
1 pallister-hall syndrome 32.8 GLI2 IGF1
2 lymphocytic hypophysitis 32.3 GH1 POMC
3 combined pituitary hormone deficiencies, genetic forms 32.3 GLI2 HESX1 LHX4 POU1F1 PROP1
4 combined pituitary hormone deficiency 31.7 HESX1 LHX3 LHX4 POU1F1 PROP1
5 septooptic dysplasia 31.6 HESX1 LHX3 POU1F1 PROP1 SOX3
6 sheehan syndrome 31.5 CRH IGF1 INS POMC PRL
7 isolated growth hormone deficiency, type iii 30.7 HESX1 SOX3
8 galactorrhea 30.3 IGF1 PRL
9 isolated growth hormone deficiency 30.2 GH1 GHRH HESX1 IGF1 LHX4 POU1F1
10 gigantism 29.9 GH1 GHRH PRL
11 adenoma 29.7 GH1 IGF1 POMC PRL
12 functioning pituitary adenoma 29.6 GH1 POMC PRL
13 turner syndrome 29.6 GH1 IGF1 IGFBP3
14 isolated growth hormone deficiency, type ii 29.5 GH1 GHRH HESX1 IGF1 POU1F1
15 hypoadrenalism 29.5 CRH GH1 POMC
16 hyperthyroidism 29.4 GH1 INS PRL
17 adenohypophysitis 29.3 GH1 POMC PRL
18 diabetes insipidus 29.3 CRH INS POMC PRL
19 secondary adrenal insufficiency 29.3 IGF1 IGFBP3 INS
20 isolated growth hormone deficiency, type ib 29.3 GH1 GHRH IGF1 IGFBP3
21 acth deficiency, isolated 29.1 CRH POMC
22 kallmann syndrome 29.0 GNRH1 HESX1 LHX3 PROP1
23 hyperinsulinism 29.0 GH1 IGF1 IGFBP3 INS
24 pituitary hormone deficiency, combined, 2 29.0 GH1 HESX1 IGF1 LHX3 LHX4 POMC
25 hypogonadotropism 29.0 GNRH1 PRL
26 pituitary carcinoma 28.9 CRH POMC PRL
27 growth hormone deficiency 28.7 GH1 GHRH HESX1 IGF1 IGFBP3 SOX3
28 chiasmal syndrome 28.6 GNRH1 POMC PRL
29 pituitary hypoplasia 28.6 HESX1 LHX3 LHX4 POU1F1 PRL SOX3
30 pituitary apoplexy 28.5 GNRH1 INS POMC PRL
31 hypothalamic disease 28.5 CRH GH1 GHRH GNRH1 POMC PRL
32 pituitary tumors 28.3 GH1 IGF1 POMC POU1F1 PRL PROP1
33 pituitary stalk interruption syndrome 28.3 GH1 HESX1 LHX4 POU1F1 PRL SOX3
34 empty sella syndrome 28.0 GH1 GNRH1 IGF1 POMC PRL
35 hyperprolactinemia 27.7 GH1 GNRH1 IGF1 POMC PRL
36 amenorrhea 27.7 CRH GNRH1 POMC PRL
37 craniopharyngioma 27.4 GH1 GNRH1 IGF1 INS POU1F1 PRL
38 insulin-like growth factor i 27.3 GH1 GHRH IGF1 IGFBP3 INS PRL
39 acromegaly 27.0 GH1 GHRH IGF1 IGFBP3 INS POMC
40 hypothyroidism 26.8 GH1 HESX1 IGF1 IGFBP3 LHX3 POMC
41 chromophobe adenoma 26.7 GH1 GHRH GNRH1 INS POMC PRL
42 hyperpituitarism 26.4 GH1 GHRH IGF1 IGFBP3 INS POMC
43 anorexia nervosa 26.1 CRH GH1 GHRH IGF1 IGFBP3 POMC
44 pituitary gland disease 23.6 CRH GH1 GHRH GNRH1 HESX1 IGF1
45 choroideremia hypopituitarism 12.0
46 anterior pituitary insufficiency, familial 12.0
47 familial hypopituitarism 12.0
48 arthrogryposis, distal, with hypopituitarism, mental retardation, and facial anomalies 11.8
49 hypopituitarism, congenital, with central diabetes insipidus 11.8
50 midline malformations, multiple, with limb abnormalities and hypopituitarism 11.8

Graphical network of the top 20 diseases related to Hypopituitarism:



Diseases related to Hypopituitarism

Symptoms & Phenotypes for Hypopituitarism

MGI Mouse Phenotypes related to Hypopituitarism:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.37 HESX1 GHRH IGF1 GLI2 IGFBP3 GNRH1
2 growth/size/body region MP:0005378 10.29 CRH HESX1 GHRH IGF1 GLI2 IGFBP3
3 homeostasis/metabolism MP:0005376 10.28 CRH GHRH IGF1 GLI2 IGFBP3 GNRH1
4 nervous system MP:0003631 10.17 CRH HESX1 GHRH IGF1 GLI2 GNRH1
5 integument MP:0010771 10.01 GNRH1 CRH IGF1 GLI2 IGFBP3 INS
6 liver/biliary system MP:0005370 9.91 GNRH1 CRH GHRH IGFBP3 INS PRL
7 hearing/vestibular/ear MP:0005377 9.85 HESX1 IGF1 GLI2 POU1F1 LHX3
8 reproductive system MP:0005389 9.85 GHRH IGF1 GLI2 GNRH1 POU1F1 INS
9 renal/urinary system MP:0005367 9.73 GNRH1 CRH IGF1 IGFBP3 INS POMC
10 respiratory system MP:0005388 9.5 CRH HESX1 IGF1 GLI2 IGFBP3 PROP1
11 skeleton MP:0005390 9.23 GNRH1 CRH IGF1 GLI2 IGFBP3 POU1F1

Drugs & Therapeutics for Hypopituitarism

Drugs for Hypopituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-23-7 5754
2
Testosterone Approved, Investigational Phase 4,Phase 2,Not Applicable 58-22-0 6013
3
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
4
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
5
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
6
Cosyntropin Approved Phase 4 16960-16-0 16129617
7
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
8
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
9
Butyric Acid Experimental, Investigational Phase 4,Not Applicable,Early Phase 1 107-92-6 264
10 insulin Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
11 Mitogens Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
12 Cortisol succinate Phase 4,Phase 3,Not Applicable,Early Phase 1
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Not Applicable,Early Phase 1
17 Hydrocortisone acetate Phase 4,Phase 3,Not Applicable,Early Phase 1
18 Hydrocortisone-17-butyrate Phase 4,Not Applicable,Early Phase 1
19 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
20 Anti-Inflammatory Agents Phase 4,Not Applicable,Early Phase 1
21 Respiratory System Agents Phase 4
22 Adrenergic Agents Phase 4,Phase 3,Phase 2
23 Adrenergic Agonists Phase 4,Phase 3
24 Adrenergic alpha-Agonists Phase 4,Phase 3
25 Anabolic Agents Phase 4,Phase 2
26 Growth Hormone-Releasing Hormone Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
28 Testosterone 17 beta-cypionate Phase 4,Phase 2
29 Androgens Phase 4,Phase 2,Not Applicable
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
31 Epinephryl borate Phase 4,Phase 3,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
33 Autonomic Agents Phase 4,Phase 3
34 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
35 Adrenergic beta-Agonists Phase 4
36 Mydriatics Phase 4
37 Vasoconstrictor Agents Phase 4
38 Anti-Asthmatic Agents Phase 4
39 Bronchodilator Agents Phase 4
40
Zinc Approved, Investigational Phase 3,Not Applicable,Early Phase 1 7440-66-6 23994
41
Benzocaine Approved, Investigational Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
42
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
43
Clonidine Approved Phase 3 4205-90-7 2803
44 tannic acid Approved, Nutraceutical Phase 3,Not Applicable
45 Hypoglycemic Agents Phase 3,Not Applicable,Early Phase 1
46 Analgesics Phase 3,Phase 2
47 Adrenergic alpha-2 Receptor Agonists Phase 3
48 Steroid Synthesis Inhibitors Phase 2, Phase 3
49 Sympatholytics Phase 3
50 Estrogen Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 246)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
2 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
3 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
4 Testosterone Gel Applied to Women With Pituitary Gland Problems Completed NCT00144391 Phase 4 Transdermal Testosterone gel
5 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
6 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
7 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
8 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
9 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
10 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
11 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
12 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
13 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
14 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
15 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
16 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
17 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
18 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
19 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
20 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
21 Easypod United States User Trial Completed NCT00689260 Phase 4
22 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
23 IGF1 Generation Test Completed NCT00145457 Phase 4
24 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
25 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
26 Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children Recruiting NCT03290235 Phase 4 PEG-somatropin
27 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT03249480 Phase 4
28 Body Composition and Adipose Tissue in HIV Recruiting NCT03226821 Phase 4 Tesamorelin
29 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT02976675 Phase 4
30 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Recruiting NCT02908958 Phase 4
31 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Recruiting NCT03015909 Phase 4 Somatropin
32 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I) Recruiting NCT02380235 Phase 4
33 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
34 Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency Terminated NCT01698944 Phase 4 somatropin
35 A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury Terminated NCT00638053 Phase 4
36 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury Terminated NCT00555009 Phase 4 Genotropin;Placebo
37 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury. Withdrawn NCT00432263 Phase 4 Genotropin (PN-180,307) Somatropin
38 Treatment of Children With Insufficient Secretion of Growth Hormone Unknown status NCT00271518 Phase 3 growth hormone (somatropin)
39 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency Completed NCT01007071 Phase 3 Human Growth Hormone (1-134);Placebo
40 Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys Completed NCT00133354 Phase 2, Phase 3 Arimidex (Anastrozole);Placebo;Growth Hormone
41 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3 Infacort®
42 Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency Completed NCT03223025 Phase 3 CinnaTropin®;Nordilet®
43 Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Completed NCT02693522 Phase 3 somatropin;Eutropin
44 Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency Completed NCT02558829 Phase 3 Macimorelin;Insulin
45 A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency Completed NCT02382939 Phase 3 somapacitan;somatropin
46 A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency Completed NCT02173821 Phase 3
47 Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency Completed NCT01502124 Phase 3 somatropin;somatropin
48 Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Completed NCT01495468 Phase 3
49 Genotropin Study Assessing Use of Injection Pen Completed NCT00965484 Phase 3
50 Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT01563926 Phase 3 somatropin

Search NIH Clinical Center for Hypopituitarism

Cochrane evidence based reviews: hypopituitarism

Genetic Tests for Hypopituitarism

Genetic tests related to Hypopituitarism:

# Genetic test Affiliating Genes
1 Hypopituitarism 29

Anatomical Context for Hypopituitarism

MalaCards organs/tissues related to Hypopituitarism:

41
Pituitary, Brain, Testes, Thyroid, Bone, Heart, Endothelial

Publications for Hypopituitarism

Articles related to Hypopituitarism:

(show top 50) (show all 790)
# Title Authors Year
1
A case series study of hypopituitarism in older patients with and without gastrointestinal symptoms. ( 29863435 )
2018
2
Congenital hypopituitarism: how to select the patients for genetic analyses. ( 29625578 )
2018
3
Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism. ( 29789996 )
2018
4
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis. ( 29752700 )
2018
5
Congenital Hypopituitarism. ( 29406008 )
2018
6
Rhabdomyolysis in a patient complicated with hypopituitarism and multiple organ dysfunction syndrome and the literature review. ( 29910183 )
2018
7
Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury. ( 29515515 )
2018
8
Pituitary in black-hypopituitarism secondary to hemosiderosis. ( 29549596 )
2018
9
Neonatal Hypopituitarism: Diagnosis and Treatment Approaches. ( 29739730 )
2018
10
Congenital Hyperinsulinism and Hypopituitarism Attributable to a Novel Mutation in FOXA2. ( 29329447 )
2018
11
Iatrogenic water intoxication in a female adolescent with hypopituitarism. ( 29523609 )
2018
12
Granular cell tumour of the neurohypophysis: an unusual cause of hypopituitarism. ( 29732160 )
2018
13
Pathogenic copy number variants in patients with congenital hypopituitarism associated with complex phenotypes. ( 29265571 )
2018
14
A case series of closed head trauma with pituitary stalk disruption resulting in hypopituitarism. ( 29477026 )
2018
15
DIFFERENTIAL REGULATION OF 11 I^ -HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVITY IN PATIENTS WITH DIFFERING AETIOLOGIES OF HYPOPITUITARISM. ( 29975580 )
2018
16
Hormone-replacement Therapy for Hepatopulmonary Syndrome and NASH Associated with Hypopituitarism. ( 29910217 )
2018
17
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. ( 29313195 )
2018
18
Next generation sequencing panel based on single molecule molecular inversion probes for detecting genetic variants in children with hypopituitarism. ( 29739035 )
2018
19
Craniopharyngeal canal, morning glory disc anomaly and hypopituitarism: what do they have in common? ( 29977576 )
2018
20
Reduced Hepatocellular Expression of Canalicular Transport Proteins in Infants with Neonatal Cholestasis and Congenital Hypopituitarism. ( 29935878 )
2018
21
Metabolic Syndrome in Hypopituitarism. ( 29895033 )
2018
22
Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. ( 29928263 )
2018
23
Intracranial germinoma causing cerebral haemiatrophy and hypopituitarism. ( 29378909 )
2018
24
Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques. ( 29678524 )
2018
25
Anterior hypopituitarism in a patient with amyloidosis secondary to Crohn's disease: a case report. ( 29929552 )
2018
26
Cerebrofacial arteriovenous metameric syndrome with hypopituitarism: a rare association. ( 29330274 )
2018
27
Hypopituitarism 3 and 12 months after traumatic brain injury and subarachnoid haemorrhage. ( 29283287 )
2018
28
Neonatal hypoglycemia, early-onset diabetes and hypopituitarism due to the mutation in EIF2S3 gene causing MEHMO syndrome. ( 29303605 )
2018
29
Hypopituitarism after gamma knife radiosurgery for pituitary adenoma. ( 28537768 )
2017
30
Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment. ( 28295551 )
2017
31
Novel FOXA2 mutation causes Hyperinsulinism, Hypopituitarism with Craniofacial and Endoderm-derived organ abnormalities. ( 28973288 )
2017
32
Russell's viper envenomation: acute hypopituitarism or acute primary adrenal insufficiency. ( 28339821 )
2017
33
IgG4-related Hypophysitis with Subtle Hypopituitarism in an Elderly Diabetic Patient: Is Treatment or Observation Preferable? ( 28924128 )
2017
34
Getting to the heart of hypopituitarism. ( 28765432 )
2017
35
Advances in understanding hypopituitarism. ( 28299199 )
2017
36
Hyponatraemia and hypopituitarism: an easily missed entity. ( 28954609 )
2017
37
Hospitalisation in Children with Adrenal Insufficiency and Hypopituitarism: Is There a Differential Burden between Boys and Girls and between Age Groups? ( 28898882 )
2017
38
Etiology of Hypopituitarism in Adult Patients: The Experience of a Single Center Database in the Serbian Population. ( 28702053 )
2017
39
Multi-genic pattern found in rare type of hypopituitarism: a whole-exome sequencing study of Han Chinese with pituitary stalk interruption syndrome. ( 28707430 )
2017
40
Getting to the heart of hypopituitarism. ( 28365624 )
2017
41
Diabetes insipidus and hypopituitarism in HIV: an unexpected cause. ( 28620498 )
2017
42
Impact of etiology, age and gender on onset and severity of hyponatremia in patients with hypopituitarism: retrospective analysis in a specialised endocrine unit. ( 28913704 )
2017
43
Analysis of Factors Related to Hypopituitarism in Patients with Nonsellar Intracranial Tumor. ( 28552700 )
2017
44
Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. ( 28597171 )
2017
45
Sex steroids and the GH axis: Implications for the management of hypopituitarism. ( 28477733 )
2017
46
A heterozygous microdeletion of 20p12.2-3 encompassing PROKR2 and BMP2 in a patient with congenital hypopituitarism and growth hormone deficiency. ( 28586151 )
2017
47
Brain Malformations Do Not Predict Hypopituitarism in Young Children with Optic Nerve Hypoplasia. ( 28848142 )
2017
48
A Case of Congenital Hypopituitarism Associated With a 1p31 Microdeletion: A Possible Role for<i>LEPR</i>and<i>JAK1</i>. ( 29264484 )
2017
49
Response: Russell's viper envenomation: acute hypopituitarism or acute primary adrenal insufficiency. ( 28339808 )
2017
50
Hypopituitarism (Panhypopituitarism) ( 29262053 )
2017

Variations for Hypopituitarism

Expression for Hypopituitarism

Search GEO for disease gene expression data for Hypopituitarism.

Pathways for Hypopituitarism

Pathways related to Hypopituitarism according to KEGG:

37
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

GO Terms for Hypopituitarism

Cellular components related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
2 extracellular space GO:0005615 9.61 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
3 insulin-like growth factor ternary complex GO:0042567 9.26 IGF1 IGFBP3
4 insulin-like growth factor binding protein complex GO:0016942 9.16 IGF1 IGFBP3
5 endosome lumen GO:0031904 8.8 GH1 INS PRL

Biological processes related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.99 GLI2 LHX3 LHX4 POU1F1 PROP1
2 cell-cell signaling GO:0007267 9.92 GHRH GNRH1 INS POMC
3 negative regulation of apoptotic process GO:0043066 9.91 GLI2 GNRH1 IGF1 INS LHX3 LHX4
4 cellular protein metabolic process GO:0044267 9.84 IGF1 IGFBP3 INS PRL
5 positive regulation of MAPK cascade GO:0043410 9.83 IGF1 IGFBP3 INS
6 animal organ morphogenesis GO:0009887 9.81 LHX3 LHX4 PROP1
7 positive regulation of cell proliferation GO:0008284 9.8 CRH GHRH GLI2 IGF1 INS POU1F1
8 glucose homeostasis GO:0042593 9.78 IGF1 INS POMC
9 lung development GO:0030324 9.76 CRH GLI2 LHX3
10 female pregnancy GO:0007565 9.75 CRH GNRH1 PRL
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.74 GH1 IGF1 INS
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 GH1 IGF1 INS
13 response to nutrient levels GO:0031667 9.71 GH1 IGF1 INS PRL
14 regulation of signaling receptor activity GO:0010469 9.7 GH1 GHRH GNRH1 IGF1 INS POMC
15 dorsal/ventral pattern formation GO:0009953 9.69 GLI2 LHX3 PROP1
16 positive regulation of DNA replication GO:0045740 9.67 GLI2 IGF1 INS
17 positive regulation of mitotic nuclear division GO:0045840 9.66 IGF1 INS
18 positive regulation of JAK-STAT cascade GO:0046427 9.65 GH1 PRL
19 positive regulation of glycolytic process GO:0045821 9.64 IGF1 INS
20 motor neuron axon guidance GO:0008045 9.64 LHX3 LHX4
21 positive regulation of insulin receptor signaling pathway GO:0046628 9.63 IGF1 INS
22 positive regulation of multicellular organism growth GO:0040018 9.63 GH1 GHRH POU1F1
23 positive regulation of glycogen biosynthetic process GO:0045725 9.62 IGF1 INS
24 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 PRL
25 hypothalamus development GO:0021854 9.6 CRH SOX3
26 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.56 IGFBP3 POU1F1
27 somatotropin secreting cell differentiation GO:0060126 9.52 POU1F1 PROP1
28 adenohypophysis development GO:0021984 9.5 GHRH POU1F1 PROP1
29 medial motor column neuron differentiation GO:0021526 9.43 LHX3 LHX4
30 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
31 pituitary gland development GO:0021983 9.02 GLI2 HESX1 LHX3 POU1F1 SOX3
32 regulation of transcription, DNA-templated GO:0006355 10.25 GLI2 HESX1 INS LHX3 LHX4 POU1F1
33 negative regulation of transcription by RNA polymerase II GO:0000122 10.05 GLI2 HESX1 POU1F1 PROP1 SOX3
34 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 GLI2 IGF1 LHX3 LHX4 POMC POU1F1

Molecular functions related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.87 GLI2 HESX1 LHX3 LHX4 POU1F1 PROP1
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 GLI2 HESX1 LHX3 POU1F1
3 sequence-specific DNA binding GO:0043565 9.63 GLI2 HESX1 LHX3 LHX4 POU1F1 PROP1
4 insulin receptor binding GO:0005158 9.4 IGF1 INS
5 insulin-like growth factor receptor binding GO:0005159 9.37 IGF1 INS
6 receptor activator activity GO:0030546 9.26 IGF1 INS
7 hormone activity GO:0005179 9.17 CRH GH1 GNRH1 IGF1 INS POMC
8 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hypopituitarism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....